|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
Loss of the intrinsic FGF7/FGF10-type 2 FGF receptor (FGFR2) pathway and gain of the ectopic type 1 FGF receptor (FGFR1) pathway are associated with the progression to malignancy in prostate cancer (PCa) and many other epithelial originating lesions.
|
30761180 |
2019 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
Importantly, the KLK2-FGFR2 fusion represents a novel target for precision therapies and should be screened for in men with prostate cancer.
|
31043681 |
2019 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, we tested the possibility that FGFR2 negatively regulates the hypoxia-triggered metastasis of prostate cancer.
|
30837551 |
2019 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
The serum expression levels of miR-628, prostate-specific antigen, fibroblast growth factor 1, and FGFR2 were examined in patients with PCa.
|
31316598 |
2019 |
|
Malignant neoplasm of prostate
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
FGFR-2 IIIb is mainly expressed in normal epithelial cells, as well as in oral mucosal, esophageal, gastric, colorectal, pancreatic, pulmonary, breast, endometrial, cervical, and prostate cancers.
|
28930565 |
2018 |
|
Malignant neoplasm of prostate
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Application of this assay on prospective patient samples uncovered OLFM4 as a novel RET fusion partner in a small-bowel cancer and led to the discovery of a KLK2-FGFR2 fusion in a patient with prostate cancer who subsequently underwent treatment with a pan-fibroblast growth factor receptor inhibitor.
|
28802831 |
2017 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
Abnormalities of FGFR2 have been shown in advanced prostate cancer or prostate cancer cell lines, and we previously demonstrated the tumor-suppressive effects of the restoration of FGFR2IIIb in prostate cancer cells.
|
24839986 |
2014 |
|
Malignant neoplasm of prostate
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer.
|
23558953 |
2013 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
FGFR2, WWOX, E-Cadherin, PKCmu, and RASLL1A did not display noteworthy methylation in pCA (0-1%) or in BPH.
|
16956712 |
2007 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings propose that decreased expression of not only FGFR2(IIIb) but also FGFR2(IIIc) isoforms may be a critical step in prostate cancer progression and furthermore suggest that FGFR2(IIIb) expression could be used as a marker for prostate cancer evolution from androgen-dependent to androgen-independent status.
|
12111699 |
2002 |
|
Malignant neoplasm of prostate
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In most cases of prostate cancer there are no changes in alternative splicing of FGF receptors, but in a subgroup there is increased expression of the FGFR-2 IIIc isoform.
|
11170144 |
2001 |
|
Malignant neoplasm of prostate
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
FGFR2 mutations in the-FGF binding domain and the TMD are not frequent events in human prostate cancer.
|
11069376 |
2000 |
|
Malignant neoplasm of prostate
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, we have observed overexpression of both FGFR-1 and FGFR-2 in the prostate cancer epithelial cells in a subset of prostate cancers and that such overexpression is correlated with poor differentiation.
|
10353739 |
1999 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
RGD |
Highly malignant prostate tumor cells, which have lost the FGFR2 tyrosine kinase, retain the cellular response mechanisms to it.
|
9537256 |
1998 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings lend support to the hypothesis that that loss of FGF-R2(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.
|
9444954 |
1997 |